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Background. Nonfunctional pancreatic neuroendocrine tumors (NF-PNETs) are rare tumors with highly
variable outcome. Current guidelines recommend surveillance for small tumors (#2 cm), but a scientific
basis for such recommendation is scarce.
Methods. Patients who underwent surgery for NF-PNET during 2001–2013 were identified from a
prospectively maintained database and reviewed retrospectively.
Results. Fifty-eight patients that had undergone an operative procedure for NF-PNET were identified.
Forty-one patients (71%) were symptomatic. Median size of the tumor was 2.5 cm (range 0.9–12.0 cm).
WHO 2010 grade was predictive of both overall- and disease-free survival (P < .001), whereas size alone
was not. Twenty-four patients had a small NF-PNET (#2 cm), of whom 16 were symptomatic and 8
asymptomatic. Seven patients with small symptomatic NF-PNETs showed signs of malignant behavior: 4
had lymph node metastases, 1 had liver metastases before surgery, 3 developed liver metastases, and 3
died of the disease. All 7 patients had either bile duct or pancreatic duct obstruction or both on preop-
erative imaging. On the contrary, patients with small asymptomatic NF-PNETs did not develop distant
metastases nor died of disease.
Conclusion. The 2010 grading system from the World Health Organization can be used to predict
survival. Symptomatic small NF-PNETs that caused bile and/or pancreatic duct obstruction had poor
outcome. In contrast, asymptomatic small NF-PNETs seem to have benign course, and are candidates for
surveillance. (Surgery 2015;158:1556-63.)From the Department of Abdominal Surgery, University of Helsinki, Helsinki University Hospital, Helsinki,
FinlandPANCREATIC NEUROENDOCRINE TUMORS (PNETs) are
rare neoplasms with an increasing incidence of
0.43 per 100,000 people, which is more than dou-
ble the incidence a few decades ago.1 Functional
PNETs excrete active hormones, which cause spe-
cific endocrine symptoms, whereas most PNETs
are nonfunctional pancreatic neuroendocrine tu-
mors (NF-PNET).1 Functional PNETs usually
require surgery to control the symptoms from the
excreted hormone. The decision to operate on
NF-PNETs is more difficult, especially as manyund and H. Sepp€anen contributed equally to this work.
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SURGERYNF-PNETs are found incidentally.2 Multiple neuro-
endocrine neoplasia type 1 (MEN1) and Von
Hippel-Lindau (VHL) are syndromes that predis-
pose patients for PNETs, and these patients may
harbor multiple PNETs.
For help in decision making, World Health
Organization (WHO) has developed a 3-stage
classification for PNETs based on their mitotic
activity to predict the aggressiveness of the
tumors.3,4 The dilemma in treating patients with
NF-PNET arises from the high morbidity caused
by pancreatic surgery, which needs to be balanced
against the aggressiveness of the tumor and pa-
tient’s comorbidities. Furthermore, the WHO clas-
sification requires histopathologic analysis of the
tumor, which might not be possible preoperatively,
especially in small tumors. Consequently, many
guidelines have used size to determine appro-
priate treatment. Size larger than 2 cm is used as
a cut-off between surveillance and operative treat-
ment of NF-PNETs.1,5,6 The aim of this study was
to evaluate the significance of size and symptoms
of NF-PNETs on metastases, progression, and
survival.
Table I. Baseline characteristic of the patients and
tumors
Total, n = 58 n (%)
Age, y, median (range) 60.5 (33–79)
Sex, M/F, n (%) 27 (47)/31 (53)
Charlson comorbidity index,
median (range)
3 (2–8)
Syndrome, n (%)
MEN1 9 (16)
VHL 1 (2)
HNPCC 2 (3)
Symptom, n (%)*
Pain 25 (43)
Jaundice 10 (17)
Weight loss 11 (19)
Palpable mass 2 (3)
Asymptomatic 17 (29)
Tumor localization, n (%)
Head 21 (36)
Body 11 (19)
Tail 19 (33)
Multiple 7 (12)
Tumor size, cm, median (range) 2.5 (0.9–12.0)
*Total percentage greater than 100% as some patients presented with
several symptoms.
HNPCC, Hereditary nonpolyposis colorectal cancer syndrome a.k.a.
Lynch syndrome; MEN1, multiple endocrine neoplasia type 1; VHL,
von Hippel-Lindau syndrome.
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Patients were identified from a prospectively
maintained database, which comprises patients
who underwent pancreatic surgery during 2000–
2013. Medical records, radiologic reports, and
histopathologic findings were reviewed retrospec-
tively. Patients whose postoperative histopathologic
diagnosis was PNET were included, and their
charts were retrieved. Patients who had symptoms
related to excreted hormone (functional PNETs)
were excluded. Follow-up data were obtained from
the community hospitals, which carried out the
follow-up visits. End of follow-up was defined as a
last contact marked in the patient records, or date
of death obtained from Population Register Cen-
ter. Curative intent surgery was defined as surgery
that aimed to remove all tumor tissue and included
both enucleation and formal resections but no R2-
resections. Resection of the primary tumor in the
presence of metastases or debulking surgery was
not considered as curative intent surgery.
The Charlson comorbidity index was used to
classify patient’s comorbidities. Pancreatic fistula
and delayed gastric emptying were graded by use
of the definitions by the International Study Group
of Pancreatic Surgery.7,8 Clavien-Dindo classifica-
tion was used to grade all complications. WHO
2010 classification was used to grade the tumors.3
Survival analyses using Kaplan-Meier and log-rank
test were done using SPSS 20.0 (IBM, Armonk,
NY). The study was approved by the institutional
review board and the local ethics committee.
RESULTS
Patients. Fifty-eight consecutive patients who
underwent resection for NF-PNET during 2001–
2013 were identified from the database. Baseline
characteristics of the patients are shown in Table I.
Median age was 61 years (range 33–79) and 27
(47%) were men. Ten patients (17%) had an un-
derlying syndrome making them susceptible to
PNETs (9 MEN1 and 1 VHL). Forty-one patients
(71%) had symptoms that lead to the investiga-
tions discovering NF-PNET, whereas in 17 patients
(29%) the tumor was found incidentally at imag-
ing studies made for other reasons. The most com-
mon symptom was abdominal pain (n = 25, 43%),
followed by jaundice (n = 10, 17%). Of the small
tumors (2 cm or less), 8 (33%) were asymptomatic,
3 (13%) had weight loss, 5 (21%) had jaundice,
and 11 (46%) had abdominal pain. Tumors were
located in the head in 21 patients (36%), the
body in 11 patients (19%), and the tail in 19
(33%) patients without any clear dominance ofany of the locations. Multiple NF-PNETs were
found in 7 patients (12%), of whom 5 had MEN1
syndrome, 1 VHL syndrome, and 1 hereditary non-
polyposis colorectal cancer syndrome. Among
these patients, only the patient with VHL-
syndrome was symptomatic (pain).
Surgery. Forty-six patients (79%) underwent
formal pancreatic resection, whereas 9 patients
(16 %) had their tumor enucleated (Table II). Me-
dian size of enucleated tumors was 17 mm (range
10–23 mm). Two patients (3%) underwent simulta-
neous distal pancreatectomy and enucleation of a
tumor located in the head. Total pancreatectomy
was performed on one patient (2%). Majority of
the cases were operated by open approach (45
patients, 78%), whereas 15 patients (26%) were
approached laparoscopically. Four patients under-
going a laparoscopic approach initially were con-
verted to open surgery (27%). Lymphadenectomy
was performed on 35 patients (60%). Overall, 44
patients (76%) underwent curative intent surgery,
whereas 14 (24%) underwent a debulking proce-
dure or resection of the primary tumor in spite of
metastases. Most of the patients (10 of 14) who un-
derwent debulking operation or primary tumor
resection had a large tumor ($4 cm).
Table II. Operative strategies and short-term morbidity
n (%)
Operative procedure
Pancreaticoduodenectomy 20 (35)
Median pancreatectomy 1 (2)
Distal pancreatectomy* 26 (45)
Uncinate process resection 1 (2)
Enucleation* 11 (19)
Total pancreatectomy 1 (2)
Approach
Open surgery 45 (78)
Laparoscopic converted to open surgery 4 (7)
Laparoscopic 9 (16)
Head resection, n = 21 Distal resection,*n = 26 Enucleation,*n = 11 All,yn = 58
Complications, all 13 (62) 16 (62) 8 (73) 37 (64)
Type
Pancreatic fistula
Grade A 3 (14) 9 (35) 3 (27) 14 (24)
Grade B 1 (5) 1 (4) 1 (9) 4 (7)
Grade C 1 (5) 5 (19) 3 (27) 8 (14)
Biliary leakage 3 (14) — — 3 (5)
Pulmonary embolism 1 (5) 0 0 1 (2)
Delayed gastric emptying
Grade A 0 1 (4) 0 1 (2)
Grade B 3 (14) 0 0 3 (5)
Grade C 3 (14) 0 0 3 (5)
Wound infection 1 (5) 0 0 1 (2)
Intra-abdominal abscess 4 (19) 2 (8) 0 7 (12)
Pneumonia 2 (10) 1 (4) 0 3 (5)
Severity
None 8 (38) 10 (39) 3 (27) 21 (36)
Clavien-Dindo 1-2 5 (29) 11 (42) 4 (32) 20 (34)
Clavien-Dindo 3 4 (19) 4 (15) 4 (36) 12 (21)
Clavien-Dindo 4 2 (20) 1 (4) 0 4 (7)
Clavien-Dindo 5 (death) 1 (5) 0 0 1 (2)
Hospital stay, days, median (range) 15 (7–36) 8 (5–64) 5 (3–11) 8 (3–64)
*Two patients underwent simultaneous distal pancreatectomy and enucleation.
yIncludes also complications for median (n = 1) and total (n = 1) pancreatectomy.
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after surgery (Table II). Clinically relevant
pancreatic fistula (grade B/C) was the most com-
mon complication (12 patients; 21%), followed
by delayed gastric emptying (n = 7; 12%). One pa-
tient (2 %) died after surgery. Eight of nine
enucleated tumors were WHO 2010 grade 1,
and one was grade 2. None of these patients
had recurrence or died of NF-PNET during
follow-up.
Tumor characteristics. Fifty patients (86%) had
a single NF-PNET, 3 patients (5%) had 2 NF-
PNETs, and 5 patients (9%) had 3 synchronous
NF-PNETs. Median size of the tumor was 2.5 cm
(range 0.9–12.0). Twenty-four patients (41%) had
NF-PNETof 2 cm or less. For analyses, tumors weredivided into 3 groups (Table III): small (diameter
2 cm or less), medium (2–4 cm), and large (4 cm
or larger). Metastatic lymph nodes were found in
4 patients (17%) with tumor size 2 cm or less.
The smallest tumor to have lymph node metastases
was 15 mm. Medium and large tumors had meta-
static lymph nodes in 10 (59%) and 9 patients
(53%), respectively.
Three of 22 patients (14%) with a small tumor
who had underwent a curative intent resection for
local disease had recurrence during follow-up.
Median time to recurrence was 12 months. Pri-
marily, 1 had WHO 2010 grade 2 and 2 grade 3
tumors. The smallest tumor to recur after curative
intent resection was 14 mm. Medium and large
tumors recurred in 5 of 13 (38%) and 3 of 7 (43%)
Table III. Tumor and prognosis characteristics in relation to size of the tumor
Small #2 cm,
n = 24
Medium
2 > 4 cm,
n = 17
Large $4 cm,
n = 17 All, n = 58
Patients with lymph nodes examined 9 (38) 14 (82) 12 (71) 35 (60)
Patients with metastatic lymph nodes found 4 (17) 10 (59) 9 (53) 23 (40)
WHO 2010 grade
G1 14 (58) 3 (18) 1 (6) 18 (31)
G2 6 (25) 12 (71) 12 (71) 30 (52)
G3 4 (17) 2 (12) 4 (24) 10 (17)
Neural invasion 3 (13) 8 (47) 5 (29) 16 (28)
Vascular invasion 5 (21) 9 (53) 9 (53) 23 (40)
Necrosis 1 (4) 4 (24) 3 (18) 8 (14)
Time from diagnosis to surgery, months,
median (IQR)
3 (2–6) 3 (2–8) 3 (2–7) 3 (2–6)
Distant metastases before surgery
Lymph node 0 1 (6) 0 1 (2)
Liver 1 (4) 3 (18) 7 (41) 11 (19)
Lung 0 0 2 (12) 2 (3)
Multiple distant location 0 0 1 (6) 1 (2)
Neoadjuvant therapy 1 (4) 3 (18) 4 (24) 8 (14)
Adjuvant therapy 6 (25) 9 (53) 9 (53) 24 (41)
Curative intent 23 (96) 14 (82) 7 (41) 44 (76)
Debulking/primary tumor resection 1 (4) 3 (18) 10 (59) 14 (24)
Recurrence after curative intent resection 3/22 (14) 5/13 (38) 3/7 (43) 12/42 (29)
Location of recurrence*
Local 0 1 (8) 1 (14) 3 (5)
Liver 3 (14) 5 (38) 2 (29) 10 (24)
Lymph node 0 1 (8) 0 1 (2)
Time to recurrence, mo, median (range) 12 (2–13)
n = 3
24 (3–45)
n = 5
27 (20–49)
n = 3
17 (2–49)
n = 12
Metastasectomy
Liver resection 1 (4) 3 (18) 6 (35) 10 (17)
Pancreatic resection 0 1 (6) 0 1 (2)
Disease-specific death 3 (13) 0 6 (35) 9 (16)
Follow-up, mo, median (range) 27 (1–131) 20 (0–109) 22 (0–91) 24 (0–131)
*Same patient may have recurrence in several locations.
IQR, Interquartile range; WHO, World Health Organization.
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tion for local disease.
One patient with a small primary tumor had
liver metastases at the time of the diagnosis, and
another patient with a small primary tumor un-
derwent only debulking due to local infiltration.
Three patients (13%) died because of progression
of a small NF-PNET. None of these patients had
MEN1 or VHL syndrome and all had underwent
pancreaticoduodenectomy. The smallest tumor to
cause NF-PNET-specific death was 15 mm. None of
the medium size NF-PNETs caused death during
follow-up, whereas 6 (35%) patients with a large
NF-PNET died of disease.
Effect of WHO 2010 grade and tumor size on
survival and recurrence. WHO 2010 grade was
highly correlated with both overall and disease-freesurvival (Table IV, Fig). There was no disease-
specific mortality among patients with grade 1 tu-
mors, whereas grade 2 tumors were associated
with a 7% mortality (2 patients) and grade 3 tu-
mors with a 70% mortality (7 patients). Because
WHO 2010 grade is seldom known preoperatively,
tumor size is used in decision making. Surprisingly,
size did not correlate with overall or disease-free
survival (Table IV, Fig). In overall survival analysis,
patients with a 2- to 4-cm tumor had a better prog-
nosis compared with those with small (2 cm or
less) or large (over 4 cm) tumor (Fig). There was
no statistical difference in the disease-free survival
in patients with tumors of different sizes (Fig).
Small (#2 cm) WHO 2010 grade 1 tumors.
Patients with small WHO 2010 grade 1 tumors
are of special interest, because these tumors are
Table IV. Tumor and prognosis characteristics based on WHO 2010 grade
G1, n = 18 G2, n = 30 G3, n = 10
Lymphadenectomy performed 3 (17) 23 (77) 9 (90)
Metastatic lymph nodes found 3 (17) 14 (47) 6 (60)
Neural invasion 2 (11) 8 (27) 7 (70)
Vascular invasion 4 (22) 13 (43) 7 (70)
Necrosis 0 3 (10) 5 (50)
Distant metastases before surgery
Lymph node 1 (6) 0 0
Liver 0 8 (27) 3 (30)
Lung 0 0 2 (20)
Multiple location 0 1 (3) 0
Resection margins
Curative intent resection 17 (94) 22 (73) 5 (50)
Debulking/primary tumor resection 1 (6) 8 (27) 5 (50)
Recurrence after curative intent resection for local disease 0 8 (38) 3 (75)
Type
Local 0 1 (13) 0
Liver 0 5 (63) 3 (100)
Liver + lymph node 0 1 (13) 0
Liver + local 0 1 (13) 0
Lung 0 0 0
n = 17 n = 21 n = 4
Time to recurrence, mo, median (range) — 25 (2–49) 15 (1–13)
Disease-specific death 0 2 (7) 7 (70)
WHO, World Health Organization.
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with grade 1 NF-PNET of size 2 cm or less. None of
the patients had metastases before surgery. Seven
patients (50%) underwent an enucleation proce-
dure, whereas 6 patients (43%) underwent a
formal resection (1 median pancreatectomy, 5
distal pancreatectomies). Furthermore, 1 patient
(7 %) underwent a simultaneous distal pancrea-
tectomy and enucleation procedure. Lymph nodes
were examined in 1 patient (7%), and 3 metastatic
lymph nodes were found. One patient developed a
ductal adenocarcinoma in the remnant pancreas
10 months after distal pancreatectomy. None of
the patients had recurrence or died of NF-PNET.
Symptomatic versus asymptomatic small (2 cm
or less) tumors. There were 17 patients without any
symptoms of their NF-PNETs. Eight of these
patients had small (2 cm or less) local asymptom-
atic tumor (Table V). None of the small asymptom-
atic tumors developed distant recurrence in the
follow-up or caused mortality (Table V). In
contrast, 7 patients of 16 with symptomatic small
NF-PNETs had signs of malignant behaviour: NF-
PNET recurred in liver in 3 of these patients, 4 pa-
tients had metastatic lymph nodes, 1 patient had
liver metastases before surgery, and 3 patients
died of the disease. Three of these 7 patients had
bile duct obstruction, 2 had bile and pancreaticduct obstruction, and 2 had only pancreatic duct
obstruction. One patient with bile and pancreatic
duct obstruction had also suspicion of metastatic
lymph nodes in the preoperative computed tomog-
raphy scan.
DISCUSSION
We report here 58 consecutive patients operated
for NF-PNETs at our institution during 2001–2013.
The WHO 2010 classification was found to predict
both overall and disease-free survival. Tumor size
alone did not predict survival, but a small portion
of small (2 cm or less) tumors showed malignant
behavior. Subgroup analyses on these patients
revealed that the worse outcomes were related
exclusively to symptomatic patients, of whom 25%
had metastatic lymph nodes, 19% recurred, and
19% died of disease. Furthermore, all of these
patients who had poor outcome had either bile or
pancreatic duct obstruction or both in preoperative
imaging. Asymptomatic patients with small NF-
PNETs had good prognosis. None of the patients
with small asymptomatic NF-PNET developed
distant metastases nor died of the disease.
It is evident that NF-PNET is a disease entity
with a broad spectrum of clinical behavior without
clear cut-off for a benign disease. Even though the
WHO 2010 classification shows good prognostic
Fig. (A) Overall survival after NF-PNET resection stratified by WHO 2010 grade. (B) Overall survival after NF-PNET
resection stratified by tumor size. (C) Disease-free survival after curative intent surgery for local disease stratified by
WHO 2010 grade. (D) Disease-free survival after curative intent surgery for local disease stratified by tumor size.
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tively. These findings demonstrate that size alone
cannot differentiate whether a small (2 cm or less)
NF-PNETs is benign or malignant, and other vari-
ables needs to be taken account as well (symptoms,
bile and/or pancreatic duct obstruction, and
grade if available).
Similarly, Haynes et al9 reported 39 patients
with small (2 cm or less) NF-PNETs, of which 3patients (8%) had late metastases or recurrence
and died of disease. Birnbaum et al2 showed that
7 out of 50 small NF-PNETs (14%) had metastatic
lymph nodes, which is similar to our finding
(13%).
Only 30% of our patients were asymptomatic,
and the majority had symptoms possibly associated
with the tumor. In fact, this is in contrast to many
earlier publications, were the majority of patients
Table V. Tumor and prognosis characteristics in relation to symptoms
Symptomatic,
n = 41
Asymptomatic,
n = 17
Small (#2 cm), asymptomatic
and without metastases
before surgery, n = 8
Patients with lymph nodes examined 29 (71) 6 (35) 0
Patients with metastatic lymph nodes found 18 (44) 5 (29) 0
WHO 2010 grade
G1 10 (24) 8 (47) 6 (75)
G2 22 (54) 8 (47) 2 (25)
G3 9 (22) 1 (6) 0
Neural invasion 16 (39) 1 (6) 0
Vascular invasion 21 (51) 3 (18) 0
Necrosis 6 (15) 2 (12) 0
Time from diagnosis to surgery, months, median (IQR) 2 (1–4) 5 (2–16) 11 (2–18)
Distant metastases before surgery
Lymph node 2 (5) 0 0
Liver 10 (24) 1 (6) 0
Lung 1 (2) 1 (6) 0
Multiple distant location 1 (2) 0 0
Neoadjuvant therapy 7 (17) 1 (6) 1 (13)
Adjuvant therapy 20 (49) 4 (24) 2 (25)
Curative intent 29 (71) 15 (88) 8 (100)
Debulking/primary tumor resection 12 (29) 2 (12) 0
Recurrence after curative intent resection 8/29 (28) 2/15 (13) 0
Location of recurrence*
Local 1 (3) 1 (7) 0
Liver 9 (31) 2 (13) 0
Lymph node 1 (3) 0 0
Time to recurrence, mo, median (range) 14 (6–24) 36 (27–45) —
Metastasectomy
Liver resection 5 (12) 1 (6) 0
Pancreatic resection 0 1 (6) 0
Disease-specific death 8 (20) 1 (6) 0
*Same patient may have recurrence in several locations.
IQR, Interquartile range; WHO, World Health Organization.
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material, only patients whose tumor was revealed
in a computed tomography scan performed for
completely unrelated indications were classified
as asymptomatic. In any case, the decision to oper-
ate on symptomatic patients is relatively straight-
forward compared with the ones that are
asymptomatic. Incidental NF-PNETs have been
associated with less aggressive features compared
with symptomatic tumors.2 Yet, the reported 5-
and 10-year survival rates for symptomatic and
asymptomatic NF-PNETs have been similar.9
Although symptomatic NF-PNETs do not possess
problems whether to resect them, we included
them in the analyses to show that even small NF-
PNETs may behave aggressively. Small asymptom-
atic NF-PNETs showed relatively benign course,
and none of the patients had distant recurrence
or died of the disease.The optimal operative strategy for NF-PNETs is
debatable, especially concerning small NF-PNETs.
Formal pancreatic resections (pancreaticoduode-
nectomy and distal resection) with lymphadenec-
tomy are associated with significant morbidity and
mortality as well as poor functional long-term
outcome. This needs to be balanced against the
relatively benign course of the majority of small
NF-PNETs. In our material, 11 patients (19%)
underwent enucleation, whereas 49 patients
(84%) underwent a formal pancreatic resection
(two patients underwent simultaneous distal
pancreatectomy and enucleation). Rate of compli-
cations was greater in the enucleation group
(73%) compared to the formal resection-group
(62%). This is explained by the high pancreatic
fistula rate in the enucleation group (27% grade C
pancreatic fistula). However, the overall severity of
complications was greater in the formal resection
Surgery
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(Clavien-Dindo classes 4–5, 10% vs 0 %). Although
long-term morbidity was not accessed in our study,
previous studies have shown enucleation superior
to formal resection in terms of diabetes and
exocrine pancreas insufficiency.12 Enucleated tu-
mors were all WHO 2010 grade 1 or 2, with size be-
tween 10 and 23 mm, and none of them recurred
or caused mortality. These results indicate that
enucleation is a viable option in these patients
with acceptable morbidity. It has been suggested
that tumors over 2 cm should be treated with
formal oncologic resection.2
There are limitations in our study. First, and
most important, the studied patients represent only
the cases that were operated and no comparison
was made to patients that underwent observation
alone. The surgery was performed in a tertiary
center, and no register of patients undergoing
surveillance in referring hospitals exists. Thus, no
conclusions can be made on the natural course of
NF-PNETs, and it remains unclear whether surgery
improves the survival of patients with small NF-
PNETs. The answer to this question would require a
randomized, prospective study, but because of the
rarity of this disease, this type of study would need a
multicenter approach. Second, this is a small
retrospective cohort study, which all its limitations.
However, due to the rarity of the disease, this is a
common problem in the field of PNETs.
In conclusion, the malignant potential of NF-
PNETs seems diverse with no clear cut-off criteria
for size to distinguish between benign and malig-
nant disease. Preoperative work-up should include
symptoms, size, and possibly WHO 2010 grade if
available. Surgical resection should be considered
in patients with symptomatic small NF-PNETs, who
are fit for surgery. Asymptomatic small NF-PNETs
seem to follow a benign course, and might be best
treated by close surveillance. Larger scale, prefer-
ably multicenter, studies would be needed to
confirm these results.REFERENCES
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